Skip to main
BIOX

BIOX Stock Forecast & Price Target

BIOX Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bioceres Crop Solutions Corp has demonstrated resilience through its diversified revenue streams, as evidenced by robust performance in international markets, particularly in bio-protection products and adjuvant sales in the US and Brazil. The company’s crop protection portfolio remains strong, with potential for a rebound in Argentine demand despite previous market share losses domestically. Moreover, the anticipated growth in international markets for HB4 wheat revenue highlights the company's strategic positioning to benefit from future expansion opportunities, supporting a positive long-term outlook.

Bears say

Bioceres Crop Solutions has experienced a significant decline in revenue driven by weaker demand in its Crop Protection and Crop Nutrition segments, particularly in Argentina, where revenues for Crop Nutrition dropped approximately 34% year-over-year to around $25 million. The company's transition to a licensing-based business model, moving away from seed production and breeding, has notably contributed to a staggering 75% year-over-year decrease in revenues for Seed & Integrated products, resulting in revenues of approximately $8 million. Additionally, the ongoing challenges of lower corn acreage and pricing pressures in Argentina’s fertilizer market have further exacerbated the company's financial difficulties, contributing to a negative outlook.

BIOX has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bioceres Crop Solutions Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bioceres Crop Solutions Corp (BIOX) Forecast

Analysts have given BIOX a Buy based on their latest research and market trends.

According to 3 analysts, BIOX has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bioceres Crop Solutions Corp (BIOX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.